The state-run energy transmission company's consolidated net profit fell 4% to 38.62 billion rupees ($443.5 million) in the three months to Dec. 31
Alembic's revenue from operations rose to Rs 1,692.74 crore in Q3FY25, a 3.8 per cent Y-o-Y increase from Rs 1,630.57 crore in Q3FY24
Tata Chemicals said it incurred a non-cash writedown on assets aggregating to 700 million rupees with respect to its UK operations
Margins under pressure for NBFC unit
Rivals Sun Pharma and Cipla beat third-quarter profit estimates, while Dr Reddy's missed expectations. All three drugmakers saw muted growth in the North American market, including the US
Hindustan Media Ventures Ltd (HMVL) on Monday reported a consolidated profit after tax of Rs 18 crore in the December quarter. The company had posted a loss after tax of Rs 0.82 crore in the October-December period a year ago, according to a regulatory filing by HMVL, the publisher of Hindi daily Hindustan. Its revenue from operations rose 8 per cent to Rs 197.47 crore in the third quarter. It stood at Rs 182.95 crore in the corresponding period a year ago. Total expenses of HMVL were Rs 201.68 crore, down 3.2 per cent in the December quarter. Its revenue from printing & publishing of newspapers & periodicals was Rs 179.72 crore. HMVL's revenue from Digital jumped four-fold to Rs 16.72 crore in the December quarter against Rs 4.18 crore in the corresponding quarter. Total income of HMVL, which includes other income, was Rs 221.39 crore, up 7.2 per cent. Shares of Hindustan Media Ventures Ltd settled at Rs 94.01 apiece, up 12.69 per cent from the previous close.
Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the December quarter, on the back of robust sales across markets. The company had reported a profit after tax (PAT) of Rs 358 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 2,319 crore in the third quarter as against Rs 1,855 crore in the year-ago period, Divi's Laboratories said in a regulatory filing. The drug firm noted a part of the Kakinada Project (Unit-III) commenced commercial operations from January 1, 2025. The rest of Kakinada project is being implemented and is expected to be operational in about six months, it added. "We have capitalised assets of Rs 433 crore for the quarter and of Rs 557 crore for the nine-month period of the current fiscal year. Of this, capitalisation for Kakinada Project is Rs 418 crore during the 9-month period," the drug firm stated. The company said its board has approved the re-appointme
A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North American market has weighed on domestic firms' margins
Markets Today Highlights: Smallcap shares were among the top laggards in broader markets, with the Nifty Smallcap100 index ending down by 2.13 per cent
In the past one month, SRF has outperformed the market by surging 33 per cent, due to initial signs of demand recovery in Q3FY25, as compared to 2.5 per cent decline in the BSE Sensex.
Its revenue from operations climbed 25 per cent to Rs 2,319 crore during the quarter, roughly in line with analysts' estimate of Rs 2,343 crore
Anant Raj share price slumped 8.94 per cent at Rs 580.55 a piece on the BSE in Monday's intraday trade despite the company reporting a 55 per cent increase in net profit for Q3FY25
The company's total revenue from operations stood at Rs 1,694.5 crore, down 20.6 per cent Y-o-Y, as compared to Rs 2,134 crore.
On Saturday, after market hours, Aarti Industries posted a 63 per cent decline in its consolidated net profit of Rs 46 crore as compared to Rs 124 crore year-on-year (Y-o-Y)
At 6:50 AM, GIFT Nifty futures were trading 173 points lower at 23,382, indicating a potential gap-down start for the markets
RBI's interest rate decision, quarterly earnings and global cues would be the major driving factors for equity markets this week, analysts said adding that the impact of the Union Budget could linger on this week. Trading activity of foreign investors will also be a key driver for the markets, experts noted. "US and India's manufacturing PMI for January to be released on Monday, will be the key macro data to watch out for. Investors will closely study the fine prints of the Budget policies and market focus will shift back to the corporate earnings/outlook and RBI's interest rate decision to be announced on Friday," Siddhartha Khemka, Head - Research, Wealth Management, Motilal Oswal Financial Services Ltd, said. From the earnings calendar, Asian Paints, PC Jeweller, Tata Power, Titan, Apollo Tyres, Bharti Airtel, ITC,F, SBI, LIC, M&M and NHPC would announce their earnings this week. Prashanth Tapse, Senior VP (Research), Mehta Equities Ltd, said, "Will the RBI soften its stance ...
Texmaco Rail & Engineering Ltd on Sunday reported an over two-fold jump in its consolidated profit after tax to Rs 76 crore in December quarter, riding on higher deliveries of freight cars. It had posted Rs 30 crore PAT (profit after tax) in the year ago quarter, the company said in a statement. The company's total revenue from operations also surged 47.9 per cent to Rs 1,326 crore in the reporting quarter from Rs 896 crore a year ago. Texmaco's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the quarter reached Rs 139 crore, up from Rs 91 crore in October-December quarter of preceding 2023-24 fiscal. "Higher freight car deliveries drove its strong performance," Texmaco said. As of December 31, the company's order book was at Rs 7,612 crore. The company's Executive Director & Vice Chairman Indrajit Mookerjee said: "Despite a challenging market environment, Texmaco maintained a steady performance in Q3 FY25, reflecting operational stability and ...
Jaiprakash Power Ventures on Saturday reported a 26.7 per cent decline in its consolidated net profit to Rs 126.68 crore in the December quarter compared to a year ago due to lower revenues. The company had a net profit of Rs 172.85 crore in the third quarter ended on December 31, 2023, according to a regulatory filing. Total income declined to Rs 1,256.63 crore in the October-December quarter against Rs 2,213.68 crore in the year-ago period.
The management believes, that on account of ramp-up of existing products, Fermion contract, and potential commercialisation of another CDMO contract in FY26E, Ami has strong revenue visibility.
IRB Infra's total revenue from operations stood at Rs 2,025.44 crore, up 2.9 per cent year-on-year (Y-o-Y), as compared to Rs 1,968.53 crore.